Prescription drug · BLA
Jobevne (Bevacizumab-nwgd) NDC 83257-010
Bevacizumab 25 mg/mL · Injection · Intravascular · Biocon Biologics Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 83257-010-11 | 8325700101183257001011 | 1 VIAL, SINGLE-DOSE in 1 CARTON (83257-010-11) / 16 mL in 1 VIAL, SINGLE-DOSEMarketed from Apr 10, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Jobevne
- Generic name (nonproprietary)
- bevacizumab-nwgd
- Active ingredients
- Bevacizumab — 25 mg/mL
- Dosage form
- Injection
- Route
- Intravascular
- Labeler
- Biocon Biologics Inc.NDC labeler code 83257
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761175
- Marketing start
- Listing expires
- Other FDA classes
- Vascular Endothelial Growth Factor Inhibitors (Mechanism)Vascular Endothelial Growth Factor-directed Antibody Interactions (Mechanism)
- Identifiers
- Product ID 83257-010_2644fd0e-5b94-9120-bdb1-e275d982b249SPL ID 2644fd0e-5b94-9120-bdb1-e275d982b249SPL set ID 70ab1de6-fb68-aee4-a6cb-f9a0f146687fRxCUI 2712048, 2712055, 2712057, 2712058UNII 2S9ZZM9Q9V
- Pharmacologic class
- Vascular Endothelial Growth Factor Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N483257001011followed by a unit qualifier and the quantityPackage 83257-0010-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Jobevne is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first-or second-line treatment. ( 1.1 ) • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan-or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Jobevne is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) • Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carb…
Excerpt only. Read the full label for complete information.
About NDC 83257-010
- What is NDC 83257-010?
- 83257-010 is the product NDC for Jobevne (bevacizumab-nwgd), Bevacizumab 25 mg/mL injection, listed with the FDA by Biocon Biologics Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Jobevne (Bevacizumab-nwgd).
- What is the active ingredient?
- Bevacizumab.
- Who is the labeler?
- Biocon Biologics Inc., NDC labeler code 83257. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Jobevne?
- 1 other product NDC are listed under this name. See all Jobevne NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Jobevne products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Jobevnebevacizumab-nwgd | Bevacizumab 25 mg/mL | InjectionIntravascular | Biocon Biologics Inc. | 83257-009 | 83257-0009-11 |
Other NDCs under BLA 761175
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Jobevnebevacizumab-nwgd | Bevacizumab 25 mg/mL | InjectionIntravascular | Biocon Biologics Inc. | 83257-009 |